EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ — Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex…